
Patience I. Odeniyide, MD, PhD
Pediatric Medical OncologySarcoma and Connective Tissue Medical Oncology
Highlights
Age Groups Seen
- Young Adult 18-25
- Adult 26-64
- Older Adult 65+
Languages
- English
In-Network Plans
View All Accepted Plans (12)Gender
FemaleJohns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Patience I. Odeniyide
Primary Academic Title
Assistant Professor of Oncology
Johns Hopkins Physician
Background
Dr. Odeniyide is an Assistant Professor in the Division of Pediatric Oncology. Her research focuses on RAS-directed therapies for pediatric rhabdomyosarcoma and her clinical expertise is in the treatment of pediatric solid tumors. Dr. Odeniyide received her undergraduate degree from the University of North Carolina at Chapel Hill and earned her MD from Indiana University School of Medicine. She did her general pediatric residency at the University of North Carolina at Chapel Hill and completed her pediatric hematology/oncology fellowship at Johns Hopkins/ NIH Pediatric Oncology Branch Pediatric Hematology/Oncology joint fellowship training program in 2017. She completed her Ph.D. in cellular and molecular medicine at Johns Hopkins School of Medicine in 2022.
Dr. Odeniyide aims to develop and implement novel molecularly targeted therapeutics to treat pediatric cancers with genetic alterations. Her research is focused on the application of small molecule therapeutics for tumors with RAS mutations, a common mutation in cancer for which few effective targeted therapies exist. Her goal is that her research will bring more effective therapeutic options for pediatric sarcoma patients.
Find a Clinical Trial
View all trials by this principal investigator.
Recent News Articles and Media Coverage
Pursuing a New Path, Johns Hopkins Medicine (November 11, 2022)
Targeting oncogenic HRAS via vertical RAS pathway inhibition in HRAS-mutated human rhabdomyosarcoma, YouTube (June 8, 2022)
Additional Academic Titles
Assistant Professor of Pediatrics
Selected Publications
Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene. 2022 Apr 22. doi: 10.1038/s41388-022-02305-x. Epub ahead of print. PMID: 35459782
Memberships
- American Association for Cancer Research
- American Academy of Pediatrics
- Children’s Oncology Group
Locations
- Johns Hopkins Children's Center
- 1800 Orleans Street, Bloomberg 11N, Baltimore, MD 21287
- Get Directions
- phone: 410-955-8751
- fax: 410-614-1802
Expertise
Education
- Fellowship: Johns Hopkins University School of Medicine, Pediatric Oncology, 2022
- Graduate School: Johns Hopkins University School of Medicine, Cellular and Molecular Medicine, PhD, 2022
- Residency: UNC Medical Center, Pediatrics, 2017
- Medical Education: Indiana University School of Medicine, Medicine, MD, 2014
Board Certifications
- Pediatric Hematology-Oncology: American Board of Pediatrics, 2021
- Pediatrics: American Board of Pediatrics, 2018
Insurance
- Aetna
- CareFirst
- Cigna
- First Health
- Geisinger Health Plan
- HealthSmart/Accel
- Johns Hopkins Health Plans
- MultiPlan
- Pennsylvania's Preferred Health Networks (PPHN)
- Point Comfort Underwriters
- Private Healthcare Systems (PHCS)
- Veteran Affairs Community Care Network (Optum-VACCN)